Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Victor Bulto
Pharma
Novartis' BTK inhibitor wins FDA approval in chronic hives
Novartis' Rhapsido has become the first oral BTK inhibitor approved for chronic spontaneous urticaria.
Angus Liuu
Sep 30, 2025 6:40pm
Kisqali off to a 'very rapid' launch in early breast cancer: CEO
Jan 31, 2025 11:28am
What does Novartis' 'US first' mindset mean? US chief explains
Jan 17, 2023 11:54am
Novartis combines pharma, oncology in major restructuring
Apr 4, 2022 4:23am
Novartis wins Leqvio nod, aims to avoid pitfalls of other PCSK9s
Dec 22, 2021 8:55pm
Novartis names new U.S. pharma chief as exec reshuffle continues
Aug 13, 2019 11:37am
